SkinHealth Systems Unveils New Hydrafacial™ and HydraScalp® with Keravive™ Clinical Data at the 2026 Science of Skin Summit

Two new clinical studies show statistically significant improvements in scalp and skin quality with HydraScalp and Hydrafacial regimens.

Rhea-AI Summary

SkinHealth Systems (SKIN) will present new clinical data for its Hydrafacial™ and HydraScalp™ with Keravive™ treatments at the Science of Skin Summit in Austin, Texas, on September 17-20, 2026.

A randomized, evaluator-blinded study of a single HydraScalp treatment showed significantly improved scalp hydration, reduced dryness and visible adherent dandruff, enhanced scalp smoothness, and maintenance of epidermal barrier integrity, supporting an optimized scalp microenvironment for long-term scalp and hair health. A Phase IV open-label study of monthly Deluxe Hydrafacial treatments with the ReGen GF™ Booster across Fitzpatrick skin types I–VI found that 100% of subjects had Global Aesthetic Improvement, with statistically significant gains in skin hydration and quality, including skin roughness, wrinkles, elasticity, and pore size.

The e-posters will be available on touchscreen monitors and in the summit mobile app.

Positive

• Hydrafacial Phase IV study: 100% of subjects showed Global Aesthetic Improvement
• Hydrafacial regimen delivered statistically significant improvements in hydration, roughness, wrinkles, elasticity, and pore size
• Single HydraScalp treatment significantly improved scalp hydration and reduced dryness and visible adherent dandruff
• HydraScalp improved smoothness while maintaining epidermal barrier integrity, supporting scalp and hair health foundation
• Benefits and tolerability for Hydrafacial observed across Fitzpatrick skin types I–VI, broadening potential user base

Negative

• None.

Market Context

SKIN’s pre-headline 24-hour change was 0.01%; the Sep 8 Hydrafacial enhancer launch recorded an 8.03...

Analysis

SKIN’s pre-headline 24-hour change was 0.01%; the Sep 8 Hydrafacial enhancer launch recorded an 8.03% reaction, providing a related platform reference for this release’s additional Hydrafacial clinical findings.

Key Figures

Global Aesthetic Improvement: 100% of subjects Study phase: Phase IV Treatment design: Single treatment +2 more

Global Aesthetic Improvement

100% of subjects

Phase IV Hydrafacial study

Study phase

Phase IV

Monthly Hydrafacial treatment study

Treatment design

Single treatment

HydraScalp with Keravive study

Treatment schedule

Monthly treatments

Hydrafacial study

Skin-type range

Fitzpatrick skin types I-VI

Hydrafacial study

Historical Context

1 past event · Latest: Sep 08

1 event

1. Sep 08

   Hydrafacial enhancer launch

   24h Move

   +8.0%

   Hydrafacial enhancers launched with reported improvements in exfoliation and participant skin appearance

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

evaluator-blinded, epidermal barrier integrity, phase iv, open-label, +1 more

5 terms

evaluator-blinded medical

"A randomized, evaluator-blinded clinical study evaluated the effects"

Evaluator-blinded means the people who measure or judge outcomes in a clinical study do not know which participants received the experimental treatment versus a control, which reduces conscious or unconscious bias in how results are recorded or interpreted. For investors, evaluator blinding increases confidence that reported benefits or side effects are real rather than influenced by expectations, making trial data more trustworthy when assessing a product’s commercial and regulatory prospects.

epidermal barrier integrity medical

"hydration, desquamation, epidermal barrier integrity and overall scalp quality"

The condition of the skin’s outermost layer and its ability to act as a protective seal that keeps moisture in and harmful microbes and irritants out. Measuring epidermal barrier integrity assesses how intact and effective that “seal” is — like judging whether a house’s exterior walls keep out rain and pests. It matters to investors because changes in barrier integrity are often primary clinical endpoints, safety markers, and regulatory or marketing considerations for dermatology and skincare products.

phase iv medical

"This Phase IV open-label study evaluated changes in skin hydration"

Phase IV is the stage of testing that happens after a drug or medical product has received regulatory approval and is used widely by patients. Think of it as ongoing real-world monitoring—like watching how a car performs after thousands have been sold—to spot rare side effects, long-term benefits, or new uses; findings can change labels, prompt safety warnings, or alter sales and investor confidence.

open-label medical

"This Phase IV open-label study evaluated changes in skin hydration"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

fitzpatrick skin types medical

"participants with Fitzpatrick skin types I-VI"

A six-category system that classifies human skin by how it reacts to ultraviolet light, ranging from very fair skin that always burns to very dark skin that rarely burns. Think of it like a numerical label for how likely skin is to burn or tan when exposed to sun. Investors encounter it in dermatology, cosmetics, sunscreen regulation, and clinical trials because it guides product testing, safety claims, labeling, and market targeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HydraScalp with Keravive study highlights improvements in scalp hydration and overall scalp quality following a single treatment

Hydrafacial study shows improvements in skin hydration and overall skin quality following a series of Hydrafacial treatments across all Fitzpatrick skin types I-VI

LONG BEACH, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems (NASDAQ: SKIN), home to flagship brand Hydrafacial™, today announced that findings from two new clinical studies evaluating HydraScalp™ with Keravive™ and Hydrafacial™ treatments will be presented at the Science of Skin Summit, September 17-20, 2026, in Austin, Texas.

The research evaluates the effects of a single HydraScalp treatment on key measures of the scalp microenvironment, as well as changes in skin hydration and overall skin quality following a series of monthly Hydrafacial treatments across Fitzpatrick skin types I-VI.

“SkinHealth Systems is committed to delivering clinically validated solutions that providers can confidently integrate into their practices,” said Whitney Cypes, Chief Brand and Clinical Innovation Officer of SkinHealth Systems. “The new clinical data reinforce the efficacy of Hydrafacial and HydraScalp treatments across a broad range of skin and scalp concerns, helping providers deliver meaningful benefits to nearly every client they serve.”

Clinical Evaluation of a Single HydraScalp Treatment on the Scalp Microenvironment

A randomized, evaluator-blinded clinical study evaluated the effects of a single HydraScalp treatment on hydration, desquamation, epidermal barrier integrity and overall scalp quality, key measures associated with a healthy scalp microenvironment.

Key Findings:

• Significantly improved scalp hydration while reducing dryness and the appearance of visible adherent dandruff.
• Enhanced scalp smoothness while maintaining epidermal barrier integrity.
• Optimized the scalp microenvironment, supporting a foundation for long-term scalp and hair health.
  
  

Poster Title: Optimization of the Scalp Microenvironment Following a Single HydraScalp™ Treatment: Results From a Randomized, Evaluator-Blinded Clinical Study

Author: Menas Kizoulis, Global Medical Affairs, SkinHealth Systems

Clinical Evaluation of the Benefits of Monthly Hydrafacial Treatments Across All Fitzpatrick Skin Types

This Phase IV open-label study evaluated changes in skin hydration and overall skin quality following a series of monthly Deluxe Hydrafacial treatments with the Hydrafacial ReGen GF™ Booster among participants with Fitzpatrick skin types I-VI.

Key Findings:

• 100% of subjects showed a Global Aesthetic Improvement as assessed by the expert investigator
• Statistically significant improvements were observed across multiple measures of skin hydration and skin quality, including skin roughness, and the appearance of wrinkles, elasticity, and pore size.
• Findings support the benefits of incorporating Hydrafacial treatments into a consistent monthly skin health regimen.
• Benefits and tolerability were observed across Fitzpatrick skin types I-VI, supporting the treatment’s relevance for a broad range of skin types.

Poster Title: Clinical Improvements in Skin Hydration and Overall Skin Quality Following Serial Hydrafacial^® Treatments Across Fitzpatrick Skin Types I–VI: Results From a Phase IV Open-Label Study

Authors: Ted Lain, MD, MBA, of the Austin Institute for Clinical Research, and Menas Kizoulis, Global Medical Affairs, SkinHealth Systems

E-Posters will be displayed digitally throughout the summit on multiple touchscreen monitors and accessible in the Science of Skin Summit mobile app.

About SkinHealth Systems
SkinHealth Systems (NASDAQ: SKIN) is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers. Anchored by Hydrafacial™, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus™ microneedling and HydraScalp™ with Keravive™, SkinHealth Systems combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences through an omnichannel network of providers worldwide. Learn more at skinhealthsystems.com or follow us on LinkedIn. Local providers can be found at hydrafacial.com/find-a-hydrafacialist.

Contacts:
Press: press@skinhealthsystems.com
Investors: IR@skinhealthsystems.com

Source: SkinHealth Systems

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the HydraScalp™ with Keravive™ clinical study evaluate?

The randomized, evaluator-blinded HydraScalp study evaluated the effects of a single treatment on scalp hydration, desquamation, epidermal barrier integrity, and overall scalp quality, all described as key measures of a healthy scalp microenvironment.

What were the key findings from the HydraScalp™ clinical study?

The study found that a single HydraScalp treatment significantly improved scalp hydration, reduced dryness and visible adherent dandruff, enhanced scalp smoothness, and maintained epidermal barrier integrity, optimizing the scalp microenvironment to support long-term scalp and hair health.

How was the Hydrafacial™ Phase IV study designed and what did it assess?

The Phase IV open-label study assessed changes in skin hydration and overall skin quality after a series of monthly Deluxe Hydrafacial treatments using the Hydrafacial ReGen GF™ Booster in participants with Fitzpatrick skin types I–VI.

What were the main outcomes of the Hydrafacial™ Phase IV study?

The company reports that 100% of subjects demonstrated Global Aesthetic Improvement as assessed by the expert investigator. Statistically significant improvements were seen in multiple measures of skin hydration and quality, including skin roughness, the appearance of wrinkles, elasticity, and pore size.

Are the Hydrafacial™ study results relevant across different skin types?

Yes. Benefits and tolerability of the monthly Deluxe Hydrafacial regimen with ReGen GF™ Booster were observed across Fitzpatrick skin types I–VI, which the company states supports the treatment’s relevance for a broad range of skin types.

How will the clinical data be shared at the 2026 Science of Skin Summit?

The clinical findings will be presented as e-posters that are displayed digitally on multiple touchscreen monitors throughout the summit and will also be accessible in the Science of Skin Summit mobile app.